{"nctId":"NCT01079130","briefTitle":"Efficacy and Safety of Different Doses of Indacaterol","startDateStruct":{"date":"2010-02"},"conditions":["Asthma"],"count":511,"armGroups":[{"label":"Indacaterol 18.75 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol 37.5 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol 75 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol 150 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Salmeterol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmeterol","Drug: Placebo to Indacaterol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]}],"interventions":[{"name":"Indacaterol","otherNames":[]},{"name":"Salmeterol","otherNames":[]},{"name":"Placebo to Indacaterol","otherNames":[]},{"name":"Placebo to Salmeterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with a diagnosis of asthma, and:\n\n  1. Receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening\n  2. Prebronchodilator forced expiratory volume in 1 second (FEV1) at screening ≥50 and ≤90% of predicted normal\n  3. An increase of ≥12% and ≥200 mL in FEV1 over prebronchodilator value within 30 minutes after inhaling albuterol\n\nExclusion Criteria:\n\n* Smoking history \\>10 pack-years\n* Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)\n* Patients with seasonal allergy whose asthma is likely to deteriorate during the study period\n* Patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening\n* Patients who have had an intubation for a severe asthma exacerbation\n* Patients who have had an emergency room visit for an asthma attack/asthma exacerbation within 6 weeks prior to screening\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with concomitant pulmonary disease\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Any patient with lung cancer or a history of lung cancer\n* Patients with a history of certain cardiovascular comorbid conditions\n* Patients who have ever received or are currently receiving omalizumab or chronic oral corticosteroid therapy\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) After 2 Weeks of Treatment","description":"Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose. The mixed model used baseline FEV1 and FEV1 prior to and 30 minutes post inhalation of albuterol as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":"0.036"},{"groupId":"OG001","value":"2.52","spread":"0.037"},{"groupId":"OG002","value":"2.59","spread":"0.036"},{"groupId":"OG003","value":"2.54","spread":"0.037"},{"groupId":"OG004","value":"2.54","spread":"0.037"},{"groupId":"OG005","value":"2.42","spread":"0.036"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) After 1 Day of Treatment","description":"Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose on day 2. The mixed model used baseline FEV1 and FEV1 prior to and 30 minutes post inhalation of albuterol as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":"0.026"},{"groupId":"OG001","value":"2.52","spread":"0.027"},{"groupId":"OG002","value":"2.54","spread":"0.026"},{"groupId":"OG003","value":"2.60","spread":"0.026"},{"groupId":"OG004","value":"2.65","spread":"0.027"},{"groupId":"OG005","value":"2.45","spread":"0.027"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":84},"commonTop":["Headache","Cough"]}}}